leisure time -WSS

leisure time

author：entertainment 2025-10-02 20:53:08 - browse：2

The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Use doctors trained outside the U.S. to ease the physician shortage

leisure time

WSS

UpToDate has a racism problem: Dr. Stanley Goldfarb

ASCO eve: Let’s set the table for this year's meeting

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

STAT wants to know your pick for a great summer read or listen

The biotech scorecard for Q3: 15 stock

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

explore

leisure time

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Scrutiny of post

Virginia high school admissions case could be legal follow

A letter from the executive editor: The 2023 STATUS List

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Tori Bowie and the unacceptable rates of Black maternal death

Undocumented workers face uncertainty as immigration law takes effect in Florida

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

At flashy new research hub, AstraZeneca lays out ambitious growth goals

hotspot

Listen: A conversation with researcher Kevin Esvelt on biosecurity

ASCO eve: Let’s set the table for this year's meeting

Beware reading your test results before your doctor does

Being 'nonadherent' patient made me a more empathetic doctor

Being 'nonadherent' patient made me a more empathetic doctor

Fentanyl is making it harder to start addiction treatment

leisure time

leisure time

focus

leisure time